
Sign up to save your podcasts
Or


With a strong pharmaceutical sector, an ageing population and a wealth of expertise, Japan is a fascinating drug discovery and development market. In our third installment of the Spotlight on Japan mini-series, Chris Hodgens, Real Estate Practice Group partner and industry specialist, Ryosuke Tateishi, Healthcare & Life Sciences Compliance and Regulatory Partner and Tsugihiro Okada, IP and Information Technology industry expert take a closer look at the drug development framework in Japan, including regulatory approval filing, clinical trial implementation and drug development collaboration.
By Baker McKenzieWith a strong pharmaceutical sector, an ageing population and a wealth of expertise, Japan is a fascinating drug discovery and development market. In our third installment of the Spotlight on Japan mini-series, Chris Hodgens, Real Estate Practice Group partner and industry specialist, Ryosuke Tateishi, Healthcare & Life Sciences Compliance and Regulatory Partner and Tsugihiro Okada, IP and Information Technology industry expert take a closer look at the drug development framework in Japan, including regulatory approval filing, clinical trial implementation and drug development collaboration.

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners